Clinical trials: Progression, Disease
Upper Tract Urothelial Carcinoma
NECTAR Study: Neoadjuvant Toripalimab + 9MW2821 for Local UTUC
The NECTAR study is a multicenter, open-label, randomized phase II clinical trial designed to evaluate a neoadjuvant treatment strategy in patients with localized upper tract urothelial carcinoma (UTUC).
- Trial name
- NECTAR (NCT07412171)
- Testing
- Toripalimab, 9MW2821, Radical Nephroureterectomy with or without Lymph Node Dissection
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking University Third Hospital
Interstitial Lung Disease
PRospective Evaluation of Interstitial Lung DIsease Progression With Quantitative CT
The interstitial lung diseases (ILD) are a heterogenous group of conditions with varying degrees of inflammation and scarring (fibrosis) of the lungs. ILD progression is unpredictable, making prognostication challenging.
- Trial name
- PREDICT-ILD (NCT05609201)
- Testing
- HRCT Thorax, Glycocheck Endothelial Glycocalyx Assessment, Blood biomarkers
- Where
- United Kingdom
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- University of Exeter
Urinary Tract Infection Complicated, Urinary Tract Infection (cUTI)
Clinical Utility of a PCR Compared to Culture and Sensitivity Testing for the Management of cUTI in Adults.
Complicated urinary tract infections (cUTIs) often lead to the overuse of empiric antibiotics, risking inappropriate treatment and contributing to antimicrobial resistance.
- Conditions
- Urinary Tract Infection Complicated, Urinary Tract Infection (cUTI), Urinary Tract Infection (Diagnosis)
- Trial name
- PCR (NCT06996301)
- Testing
- Treatment guided by the PCR results, Treatment guided by the C&S results
- Where
- 6 sites in United States
- Volunteers
- 773 people
- Sponsor
- Doc Lab Inc
Community-acquired Pneumonia
Clarithromycin Treatment to Prevent Sepsis Progression in CAP (REACT)
The primary objective of the REACT randomized clinical trial (RCT) is to optimize the clinical benefit from adjunctive clarithromycin treatment shown in the ACCESS trial and to provide evidence for the clinical benefit of early…
- Trial name
- REACT (NCT06294600)
- Testing
- Clarithromycin 500mg, Tablets
- Where
- 24 sites in Greece
- Volunteers
- 330 people
- Sponsor
- Hellenic Institute for the Study of Sepsis
Stargardt, Stargardt's Disease
An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene
This is an Observational Study to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene This is a multicenter study which will enroll approximately 75…
- Conditions
- Stargardt, Stargardt's Disease, Stargardt Disease, STGD1
- Trial name
- POLARIS (NCT06435000)
- Where
- 20 sites in United States, Germany and 1 more
- Volunteers
- 75 people
- Sponsor
- Splice Bio
Strabismic Amblyopia, Bilateral
Progression of Stereopsis Recovery in Strabismic Patients: A One-Month and Three-Month Post-Surgery Evaluation
This prospective longitudinal observational study aims to assess stereopsis recovery in strabismic patients at one month and three months post-corrective surgery.
- Trial name
- NCT06913400
- Testing
- Stereopsis Recovery
- Where
- Pakistan
- Volunteers
- 34 people
- Sponsor
- Superior University
COVID-19, SARS-CoV-2
Azithromycin for COVID-19 Treatment in Outpatients Nationwide
This individually randomized telemedicine-based trial aims to evaluate the efficacy of a single dose of azithromycin for prevention of progression of COVID-19 in patients with a recent positive SARS-CoV-2 test who are not…
- Trial name
- ACTION (NCT04332107)
- Testing
- Azithromycin
- Where
- United States
- Volunteers
- 263 people
- Sponsor
- Thomas M. Lietman
Sepsis, Sepsis Associated DIC
A Study to Learn About the Occurrence of Disseminated Intravascular Coagulation in People With Sepsis and Further Worsening of Sepsis
This is an exploratory study in which data from people with sepsis (a serious condition in which the body responds to an infection that damages vital organs) admitted to an Intensive care unit (ICU) who will receive treatment are…
- Trial name
- NCT06986798
- Testing
- Local standard medical care
- Where
- 31 sites in Austria, Belgium and 5 more
- Volunteers
- 150 people
- Sponsor
- Bayer
Chronic Hepatitis C, Liver Fibrosis
Prevention of Disease Progress in Chronic Hepatitis C Patients With Liver Fibrosis (Study P02570AM2)(COMPLETED)
The objective of the study is to evaluate the safety and efficacy of PEG-Intron versus no treatment for the prevention of fibrosis progression in adult participants with moderate to severe liver fibrosis secondary to chronic…
- Trial name
- NCT00049842
- Testing
- peginterferon alfa-2b (SCH 54031)
- Volunteers
- 540 people
- Sponsor
- Merck Sharp & Dohme LLC
Liver Cirrhosis
Faecal Microbiota Transplantation for Liver Cirrhosis
The purpose is to investigate the effect of faecal microbiota transplantation (FMT) on complications, progression, and mortality of patients with liver cirrhosis.
- Trial name
- CHiFT (NCT04932577)
- Testing
- Faecal microbiota transplantation
- Where
- Denmark
- Volunteers
- 220 people
- Sponsor
- University of Aarhus
Moderate Aortic Valve Stenosis, Moderate Aortic Valve Regurgitation
Prospective Observational Cohort Study of Moderate Aortic Valve Disease
The objective of this research is to evaluate and predict the progression of moderate aortic stenosis and regurgitation from clinical characterization, biological, echocardiographic, and computed tomography (CT) et. al.
- Conditions
- Moderate Aortic Valve Stenosis, Moderate Aortic Valve Regurgitation, Aortic Valve Disease
- Trial name
- NCT06595992
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Cardiovascular Disease, Coronary Artery Calcification
7 Year Follow-up Study of the DanRisk Population
OBJECTIVES: To investigate the incidence of cardiovascular events as well as progression of coronary artery calcium (CAC) in healthy middle-aged subjects over a period of 7 years, and the relation to traditional as well as new…
- Conditions
- Cardiovascular Disease, Coronary Artery Calcification, Atherosclerosis
- Trial name
- NCT02913144
- Volunteers
- 1,257 people
- Sponsor
- Odense University Hospital
Myopia, Myopia Progression
Contact Lenses to Slow Myopia Progression in Adults
Myopia (nearsightedness) can continue to worsen during young adulthood, increasing the risk of sight-threatening eye diseases later in life.
- Trial name
- NCT07747311
- Testing
- Dual Focus Soft Contact Lens, Single Vision Soft Contact Lens
- Where
- United States
- Volunteers
- 152 people
- Sponsor
- University of California, Berkeley
Parkinson's Disease (PD)
Randomized, Placebo-Controlled Trial of N-acetylcysteine In Parkinson's Disease Patients: A Pilot Study
This is a study on Parkinson's disease patients, referred to Tohid Hospital of Sanandaj City. The patients receive N-acetylcysteine for one year.
- Trial name
- IRANNACPD (NCT07093944)
- Testing
- N-Acetylcysteine (NAC) Treatment
- Where
- Iran
- Volunteers
- 42 people
- Sponsor
- Kurdistan University of Medical Sciences
High Myopia, Low Concentration Atropine
Low Concentration Atropine Combined With Soft Contact Lens in Controlling Myopia Progression in Children With High Myopia
Peripheral contact lens in controlling myopia progression in high myopia children（PAM）is a prospective, single-center, randomized controlled trial with three parallel arms conducted at Beijing Tongren Hospital.
- Conditions
- High Myopia, Low Concentration Atropine, Soft Contact Lens, Children
- Trial name
- NCT07406399
- Testing
- soft peripheral defocus contact lenses, Atropine 0.04%, Atropine (0.01%)
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Beijing Tongren Hospital
Leukemia
Role of Biomarkers in Disease Progression in Samples From Patients With Acute Myeloid Leukemia
RATIONALE: Studying samples of blood, tissue, and bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT01500499
- Testing
- gene expression analysis, gene rearrangement analysis, polymerase chain reaction
- Volunteers
- 20 people
- Sponsor
- Children's Oncology Group
Glioblastoma
Multicentre Validation of How Vascular Biomarkers From Tumor Can Predict the Survival of the Patient With Glioblastoma
Despite an aggressive therapeutic approach, the prognosis for most patients with glioblastoma (GBM) remains poor. The relationship between non-invasive Magnetic Resonance Imaging (MRI) biomarkers at preoperative, postradiotherapy…
- Trial name
- ONCOhabitats (NCT03439332)
- Where
- Spain
- Volunteers
- 305 people
- Sponsor
- Juan M Garcia-Gomez
Heart Failure - NYHA II - IV
Peripheral Drivers of Heart Failure Progression - The Prospective PEDAL-HF Study
PEDAL-HF is a registry-based randomized prospective multicenter study. The investigators plan to include 1000 patients who were recently admitted with acute decompensated heart failure at five tertiary heart clinics in Germany.
- Trial name
- PEDAL-HF (NCT06656832)
- Testing
- Heart Failure network care
- Where
- Germany
- Volunteers
- 1,000 people
- Sponsor
- University of Leipzig
Pulmonary Disease, Chronic Obstructive, Adverse Effect of Glucocorticoids and Synthetic Analogues
Reduction of Corticosteroid Use in Outpatient Treatment of Exacerbated COPD
Background Chronic obstructive pulmonary disease (COPD) is a major public health issue with no curative treatment. In Switzerland estimated 5-7% of the total population are suffering from this chronic disease.
- Conditions
- Pulmonary Disease, Chronic Obstructive, Adverse Effect of Glucocorticoids and Synthetic Analogues, Disease Exacerbation
- Trial name
- RECUT (NCT02386735)
- Testing
- Prednisone
- Where
- Switzerland
- Volunteers
- 133 people
- Sponsor
- Prof. Dr. Jörg Leuppi
Multiple System Atrophy
Progression Rate of MSA Under EGCG Supplementation as Anti-Aggregation-Approach
MSA is a rapidly progressive disorder with an average survival time of about 7 years after the first clinical manifestation. No potent symptomatic treatment is currently available.
- Trial name
- PROMESA (NCT02008721)
- Testing
- EGCG as putative neuroprotective agent
- Where
- 12 sites in Germany
- Volunteers
- 92 people
- Sponsor
- Dr. Johannes Levin
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.